Difference between revisions of "Perifosine (KRX-0401)"
Jump to navigation
Jump to search
m |
Warner-admin (talk | contribs) |
||
| (9 intermediate revisions by 3 users not shown) | |||
| Line 1: | Line 1: | ||
==Mechanism of action== | ==Mechanism of action== | ||
| − | + | From the [https://www.cancer.gov/publications/dictionaries/cancer-drug?cdrid=43408 NCI Drug Dictionary]: An orally active alkyl-phosphocholine compound with potential antineoplastic activity. Targeting cellular membranes, perifosine modulates membrane permeability, membrane lipid composition, phospholipid metabolism, and mitogenic signal transduction, resulting in cell differentiation and inhibition of cell growth. This agent also inhibits the anti-apoptotic mitogen-activated protein kinase (MAPK) pathway and modulates the balance between the MAPK and pro-apoptotic stress-activated protein kinase (SAPK/JNK) pathways, thereby inducing apoptosis. | |
==Preliminary data== | ==Preliminary data== | ||
| − | ===[[Hodgkin lymphoma]]=== | + | ===[[Classical Hodgkin lymphoma]]=== |
| − | # Guidetti A, Carlo-Stella C, Locatelli SL, Malorni W, Mortarini R, Viviani S, Russo D, Marchianò A, Sorasio R, Dodero A, Farina L, Giordano L, Di Nicola M, Anichini A, Corradini P, Gianni AM. Phase II Study of Perifosine and Sorafenib Dual-Targeted Therapy in Patients with Relapsed or Refractory Lymphoproliferative Diseases. Clin Cancer Res. 2014 Sep 19. | + | # Guidetti A, Carlo-Stella C, Locatelli SL, Malorni W, Mortarini R, Viviani S, Russo D, Marchianò A, Sorasio R, Dodero A, Farina L, Giordano L, Di Nicola M, Anichini A, Corradini P, Gianni AM. Phase II Study of Perifosine and Sorafenib Dual-Targeted Therapy in Patients with Relapsed or Refractory Lymphoproliferative Diseases. Clin Cancer Res. 2014 Nov 15;20(22):5641-51. Epub 2014 Sep 19. [http://clincancerres.aacrjournals.org/content/20/22/5641.full link to original article] [https://pubmed.ncbi.nlm.nih.gov/25239609/ PubMed] |
| − | == | + | ==Also known as== |
| − | * | + | *'''Code name:''' KRX-0401 |
| − | |||
| − | [[Category: | + | [[Category:Drugs]] |
| − | [[Category: | + | [[Category:Oral medications]] |
| − | |||
[[Category:AKT1 inhibitors]] | [[Category:AKT1 inhibitors]] | ||
| − | [[Category: | + | [[Category:MEK inhibitors]] |
| − | [[Category:Investigational | + | [[Category:Investigational drugs]] |
| − | |||
Latest revision as of 01:02, 15 June 2023
Mechanism of action
From the NCI Drug Dictionary: An orally active alkyl-phosphocholine compound with potential antineoplastic activity. Targeting cellular membranes, perifosine modulates membrane permeability, membrane lipid composition, phospholipid metabolism, and mitogenic signal transduction, resulting in cell differentiation and inhibition of cell growth. This agent also inhibits the anti-apoptotic mitogen-activated protein kinase (MAPK) pathway and modulates the balance between the MAPK and pro-apoptotic stress-activated protein kinase (SAPK/JNK) pathways, thereby inducing apoptosis.
Preliminary data
Classical Hodgkin lymphoma
- Guidetti A, Carlo-Stella C, Locatelli SL, Malorni W, Mortarini R, Viviani S, Russo D, Marchianò A, Sorasio R, Dodero A, Farina L, Giordano L, Di Nicola M, Anichini A, Corradini P, Gianni AM. Phase II Study of Perifosine and Sorafenib Dual-Targeted Therapy in Patients with Relapsed or Refractory Lymphoproliferative Diseases. Clin Cancer Res. 2014 Nov 15;20(22):5641-51. Epub 2014 Sep 19. link to original article PubMed
Also known as
- Code name: KRX-0401